The product market of EPO (erythropoietin), a genetic recombinant preparation, has been targeted to attack by many major domestic as well as foreign multinational drug corporations.
A new once-a-week dosage form of EPO, which used to be administered 2 to 3 times a week for renal failure patients during hemodialysis, seems to be marketed soon in Korea.
5 companies are now on market includ...
Fees
- Email service daily and homepage access.
- $300 per month.
- 5 Email holders per each company.
- Anual contract base.
Copyright Yakup.com All rights reserved.
약업닷컴의 모든 컨텐츠는 저작권법의 보호를 받습니다. 무단 전재⋅복사⋅배포 등을 금합니다.